Madison R&D Tax Credit Overview and Benefits

R&D Tax Credits for Madison, Wisconsin Businesses

Madison, Wisconsin, is known for industries such as healthcare, education, technology, and biotechnology. Top companies in the city include Epic Systems, a leading healthcare software provider; University of Wisconsin-Madison, a prominent educational institution; Exact Sciences, a major biotechnology company; American Family Insurance, a key insurance provider; and Promega, a well-known biotechnology company. The R&D tax credit can help these businesses save on taxes by encouraging innovation and technological advancements.

find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 333 West Brown Deer Road, Milwaukee, Wisconsin is less than 90 miles away from Madison and provides R&D tax credit consulting and advisory services to Madison and the surrounding areas such as: Sun Prairie, Fitchburg, Middleton, Waunakee and Verona.

If you have any questions or need further assistance, please call or email our local Wisconsin Partner on (608) 268-8705.
Feel free to book a quick teleconference with one of our Wisconsin R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Madison, Wisconsin Patent of the Year – 2024/2025

AmebaGone LLC has been awarded the 2024/2025 Patent of the Year for groundbreaking work in microbial therapy. Their invention, detailed in U.S. Patent No. 11864559, titled ‘Therapeutic amoeba and uses thereof’, introduces a novel way to treat bacterial infections using naturally occurring, non-pathogenic amoebae.

This technology uses live amoebae that selectively consume harmful bacteria, offering an alternative to traditional antibiotics. It targets specific pathogens without harming beneficial microbes, making it especially valuable in fighting antibiotic-resistant infections.

The patent outlines therapeutic applications for agriculture, human health, and environmental cleanup. In one example, the amoebae can be applied directly to infected tissue or surfaces to reduce bacterial load. Unlike chemical treatments, the approach is biological, self-sustaining, and poses minimal environmental risk.

Amebagone’s innovation addresses a global health crisis: the rise of superbugs. By harnessing a predator-prey relationship found in nature, the company has developed a tool that works with biology rather than against it. This method may not only reduce the use of antibiotics but also help maintain microbial balance in the body and the environment. It represents a major leap forward in precision microbiology and the future of anti-infective strategies.